EUVIMEDEUVIMED entdecken
Crossref

A Novel Anti-PD-L1 Functionalized Protopanaxadiol-Liposome Loading Paclitaxel for Synergistic Immunochemical Therapy of Triple-Negative Breast Cancer

Yawen Yu iD, Ming-Yan Yang, Baifang Gong, Zhixia Wang iD, Ke Liu, Huaying Fan

Molecular Pharmaceutics · 2025

DOI: 10.1021/acs.molpharmaceut.5c00701 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2025. Verfasst von Yawen Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation…. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Paclitaxel, B7-H1 Antigen, Sapogenins. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Yantai University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chemotherapy combined with immune checkpoint blockade (ICB) has shown a significant therapeutic effect in triple negative breast cancer (TNBC). However, due to the existence of a tumor immunosuppressive microenvironment and the influence of the autoregulatory mechanism of related receptors, the response to ICB therapy is still limited; there is a low response rate of patients, and the clinical treatment success rate is still less than 20%. In this study, we developed novel chemo-immunosynergistic therapies aimed at safe and effective treatment of TNBC. A novel liposome loaded paclitaxel (PTX) was prepared using protopanaxadiol (PPD) as a membrane material to reshape the tumor microenvironment (TME) and improve the delivery of PTX in vivo. In vitro studies have demonstrated that PPD-PTX-lipo can target and reshape the TME, inhibit tumor cell proliferation and migration, and induce tumor cell apoptosis. Anti-PD-L1 was further modified on the surface of the liposome (anti-PD-L1-PPD-PTX-lipo) for chemotherapy and immunosynergistic treatment. The combination of anti-PD-L1 and liposome further promotes the uptake of liposome by tumor cells and at the same time promotes the degradation of PD-L1 in vivo to achieve long-term immunotherapy. In summary, this study has developed a highly effective immunochemical synergistic therapy that provides a new strategy for TNBC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsPaclitaxelB7-H1 AntigenSapogeninsImmune Checkpoint InhibitorsLiposomesFemaleHumansAnimalsMiceCell Line, TumorTumor MicroenvironmentApoptosisCell ProliferationXenograft Model Antitumor AssaysMice, Inbred BALB CDrug SynergismMice, Nude

Stichwörter der Autor:innen

LiposomePD-L1ProtopanaxadiolTriple negative breast cancer

Substanzen

PaclitaxelLiposomesB7-H1 AntigenSapogeninsprotopanaxadiolCD274 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universi…

ORCID-Profile: Yawen Yu, Zhixia Wang

Förderung

  • Yantai University

Zitieren

APA

Yu, Y., Yang, M. Y., Gong, B., Wang, Z., Liu, K., & Fan, H. (2025). A Novel Anti-PD-L1 Functionalized Protopanaxadiol-Liposome Loading Paclitaxel for Synergistic Immunochemical Therapy of Triple-Negative Breast Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.5c00701

Vancouver

Yu Y, Yang MY, Gong B, Wang Z, Liu K, Fan H. A Novel Anti-PD-L1 Functionalized Protopanaxadiol-Liposome Loading Paclitaxel for Synergistic Immunochemical Therapy of Triple-Negative Breast Cancer. Molecular Pharmaceutics. 2025. doi:10.1021/acs.molpharmaceut.5c00701

BibTeX
@article{Yu2025,
  author = {Yu, Yawen and Yang, Ming-Yan and Gong, Baifang and Wang, Zhixia and Liu, Ke and Fan, Huaying},
  title = {A Novel Anti-PD-L1 Functionalized Protopanaxadiol-Liposome Loading Paclitaxel for Synergistic Immunochemical Therapy of Triple-Negative Breast Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2025},
  doi = {10.1021/acs.molpharmaceut.5c00701}
}
Kostenlos starten →